SCHEMBL18342017

SCHEMBL18342017

CCOC(=O)Cc1nc2ccc(C(=O)N3CCOCC3)cc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.54
AKT1 P31749 1/20 0.53
SIRT2 Q8IXJ6 2/20 0.52
SIRT1 Q96EB6 2/20 0.52
FGFR1 P11362 3/20 0.49
FGFR2 P21802 3/20 0.49
FGFR3 P22607 3/20 0.49
KDR P35968 2/20 0.49
PIK3CD O00329 2/20 0.47
MTOR P42345 2/20 0.47
PIK3CA P42336 1/20 0.47
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PIK3CB P42338 1/20 0.44
ALDH1A1 P00352 2/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18341894 0.89 HSD17B10 (0.55) HSD17B10FGFR1FGFR2FGFR3KDR
SCHEMBL20313094 0.86 MTOR (0.51) SIRT2SIRT1FGFR1FGFR2FGFR3
SCHEMBL3378290 0.84 AKT1 (0.62) HSD17B10AKT1SIRT2SIRT1FGFR1
SCHEMBL20321253 0.80 HSD17B10 (0.55) HSD17B10HPGDALDH1A1CACNA1BAPBA1
SCHEMBL3383861 0.80 HSD17B10 (0.66) HSD17B10SIRT2SIRT1SMN1; SMN2ALDH1A1
SCHEMBL3380635 0.79 ACHE (0.55) HSD17B10AKT1FGFR1FGFR2FGFR3
SCHEMBL3730393 0.78 HSD17B10 (0.63) HSD17B10SIRT2SIRT1NPC1RAB9A
SCHEMBL3381346 0.77 HSD17B10 (0.62) HSD17B10SIRT2SIRT1NPC1RAB9A
SCHEMBL3378287 0.77 AKT1 (0.61) HSD17B10AKT1SIRT2SIRT1FGFR2
SCHEMBL14091320 0.77 ALDH1A1 (0.53) HSD17B10FGFR1FGFR2FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113214287-B HPK1 inhibitors and methods of use thereof 大学健康网络 2023-10-20 CN disclosed
US-20220002313-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2022-01-06 US disclosed
US-20220002313-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2022-01-06 US disclosed
CN-113214287-A HPK1 inhibitors and methods of use thereof 大学健康网络 2021-08-06 CN disclosed
US-11059832-B2 HPK1 inhibitors and methods of using same UNIVERSITY HEALTH NETWORK (CA) 2021-07-13 US disclosed
US-11059832-B2 HPK1 inhibitors and methods of using same UNIVERSITY HEALTH NETWORK (CA) 2021-07-13 US disclosed
CN-107922431-B HPK1 inhibitors and methods of use thereof 大学健康网络 2021-06-04 CN disclosed
EP-3322711-B1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIV HEALTH NETWORK (CA) 2021-03-10 EP disclosed
EP-3322711-B1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIV HEALTH NETWORK (CA) 2021-03-10 EP disclosed
US-20200190104-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2020-06-18 US disclosed
US-20200190104-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2020-06-18 US disclosed
US-20180179221-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2018-06-28 US disclosed
US-20180179221-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2018-06-28 US disclosed
EP-3322711-A1 HPK1 INHIBITORS AND METHODS OF USING SAME University Health Network (CA) 2018-05-23 EP disclosed
WO-2016205942-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2016-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11059832-B2 HPK1 inhibitors and methods of using same PDXK, PDK3, PDK2 HSD17B10 1233/4885AKT1 1143/4885SIRT2 1765/4885
US-20180179221-A1 HPK1 INHIBITORS AND METHODS OF USING SAME PDXK, PDK3, PDK2 HSD17B10 1233/4885AKT1 1143/4885SIRT2 1765/4885
US-20220002313-A1 HPK1 INHIBITORS AND METHODS OF USING SAME PDXK, PDK3, PDK2 HSD17B10 1201/4885AKT1 1130/4885SIRT2 1896/4885
US-20200190104-A1 HPK1 INHIBITORS AND METHODS OF USING SAME PDXK, PDK3, PDK2 HSD17B10 1233/4885AKT1 1143/4885SIRT2 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.